Slow Going With CAR T-Cell Therapy for Solid Tumors
Almost 4 years after the first chimeric antigen receptor (CAR) T-cell therapies received FDA approval, the transformative impact of the treatment on refractory hematologic malignancies has yet to translate into the field of solid tumors. The increased molecular complexity of solid tumors and lack of good antigen targets have coalesced into a formidable roadblock for […]